Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
Open Access
- 1 March 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 5 (3), 767-775
- https://doi.org/10.1158/1535-7163.mct-05-0408
Abstract
We attempted to identify potent marker genes using a new statistical analysis and developed a prediction system for individual response to platinum/paclitaxel combination chemotherapy in ovarian cancer patients based on the hypothesis that expression analysis of a set of the key drug sensitivity genes for platinum and paclitaxel could allow us to predict therapeutic response to the combination. From 10 human ovarian cancer cell lines, genes correlative in the expression levels with cytotoxicities of cisplatin (CDDP) and paclitaxel were chosen. We first selected five reliable prediction markers for the two drugs from 22 genes already known as sensitivity determinants and then identified another 8 novel genes through a two-dimensional mixed normal model using oligomicroarray expression data. Using expression data of genes quantified by real-time reverse transcription-PCR, we fixed the best linear model, which converted the quantified expression data into an IC50 of each drug. Multiple regression analysis of the selected genes yielded three prediction formulae for in vitro activity of CDDP and paclitaxel. In the same way, using the same genes selected in vitro, we then attempted to develop prediction formulae for progression-free survival to the platinum/paclitaxel combination. We therefore constructed possible formulae using different sets of 13 selected marker genes (5 known and 8 novel genes): Utility confirmation analyses using another nine test samples seemed to show that the formulae using a set of 8 novel marker genes alone could accurately predict progression-free survival (r = 0.683; P = 0.042). [Mol Cancer Ther 2006;5(3):767–75]Keywords
Other Versions
This publication has 40 references indexed in Scilit:
- Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian CancersClinical Cancer Research, 2005
- Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel ChemotherapyClinical Cancer Research, 2005
- Cancer pharmacogenomics: progress and obstacles toward the goalInternational Journal of Clinical Oncology, 2005
- Dependence of the Cytotoxicity of DNA-Damaging Agents on the Mismatch Repair Status of Human CellsCancer Research, 2004
- Cisplatin resistance is associated with deregulation in protein kinase C-δBiochemical and Biophysical Research Communications, 2004
- The Cluster of BTN Genes in the Extended Major Histocompatibility ComplexGenomics, 2001
- ALEX1, a Novel Human Armadillo Repeat Protein That Is Expressed Differentially in Normal Tissues and CarcinomasBiochemical and Biophysical Research Communications, 2001
- Cloning and Expression of Pleckstrin 2, a Novel Member of the Pleckstrin FamilyBiochemical and Biophysical Research Communications, 1999
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerThe New England Journal of Medicine, 1996
- Least Median of Squares RegressionJournal of the American Statistical Association, 1984